Heterotopic Heart Transplantation: The United States Experience
Introduction: More than 3 decades have passed since the first heterotopic heart transplantation (HHT) was reported. Nowadays, this surgical technique is used rarely, and only in patients who do not qualify for standard orthotopic heart transplantation (OHT). Current indications mainly comprise refractory pulmonary hypertension and a donor-recipient size mismatch (>20%). The objective of this study was to analyze the United States experience with HHT.
Patients and Methods: The United Network for Organ Sharing (UNOS) database between 1987 and 2007 was analyzed. Patients who underwent heart transplantation were enrolled in this study. Patients with missing transplant dates or history of retransplantation were excluded.
Results: A total of 41,379 patients underwent OHT and 178 HHT; 32,361 and 111 patients, respectively, were enrolled. Overall 1-, 5-, and 10-year survival was significantly (P < .001) better in OHT (87.7%, 74.4%, 54.4%) than HHT patients (83.8%, 59%, 35.1%). Survival in patients with transpulmonary gradients (TPG) >15 mmHg was 86.6 %, 73.3%, and 57.4% in the OHT and 93.8%, 64.8%, and 48.6% in the HHT group (P = .35). Pretransplant criteria (HHT versus OHT) with statistically significant differences (P < .05) were as follows (mean + SD): recipient weight, 78.9 + 19.9 versus 74.1 + 23.4 kg; recipient height, 174.9 + 13.9 versus 168 + 25.1 cm; and TPG 12.1 + 7.2 versus 9.6 + 6.3 mmHg.
Conclusions: The results show that HHT remains a feasible option in a highly selected patient population, with overall good results.
Alexopoulos D, Sleight P, Yacoub MH. 1988. Supraventricular tachycardia after heterotopic heart transplantation. Eur Heart J 9:1266-8.nAnyanwu AC, Banner NR, Radley-Smith R, Khaghani A, Yacoub MH. 2002. Long-term results of cardiac transplantation from live donors: the domino heart transplant. J Heart Lung Transplant 21:971-5.nBarnard CN. 1967. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 41:1271-4.nBarnard CN, Losman JG. 1975. Left ventricular bypass. S Afr Med J 49:303-12.nBarnard CN, Losman JG, Curcio CA, Sanchez HE, Wolpowitz A, Barnard MS. 1977. The advantage of heterotopic cardiac transplantation over orthotopic cardiac transplantation in the management of severe acute rejection. J Thorac Cardiovasc Surg 74:918-24.nBarnard CN, Wolpowitz A. 1979. Heterotopic versus orthotopic heart transplantation. Transplant Proc 11:309-12.nChapelier A, Vouhe P, Macchiarini P, et al. 1993. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 106:299-307.nChiu KM, Lin TY, Chu SH. 2006. Successful heterotopic heart transplant after cardiopulmonary bypass rescue of an arrested donor heart. Transplant Proc 38:1514-5.nCooper DK, Novitzky D, Becerra E, Reichart B. 1986. Are there indications for heterotopic heart transplantation in 1986? A 2- to 11-year follow-up of 49 consecutive patients undergoing heterotopic heart transplantation. Thorac Cardiovasc Surg 34:300-4.nDesruennes M, Muneretto C, Gandjbakhch I, et al. 1989. Heterotopic heart transplantation: current status in 1988. J Heart Transplant 8:479-85.nEtz CD, Welp HA, Tjan TD, et al. 2007. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 83:1697-705.nKawaguchi A, Gandjbakhch I, Pavie A, et al. 1989. Cardiac transplant recipients with preoperative pulmonary hypertension. Evolution of pulmonary hemodynamics and surgical options. Circulation 80(5 Pt 2):III90-6.nKawaguchi A, Gandjbakhch I, Pavie A, et al. 1989. Factors affecting survival after heterotopic heart transplantation. J Thorac Cardiovasc Surg 98(5 Pt 2):928-34.nKonertz W, Sheikhzadeh A, Weyand M, Friedl A, Bernhard A. 1988. Heterotopic heart transplantation: current indications for the procedure, with results in 10 patients. Tex Heart Inst J 15:159-62.nKotliar C, Smart FW, Sekela ME, et al. 1991. Heterotopic heart transplantation and native heart ventricular arrhythmias. Ann Thorac Surg 51:987-91.nLivi U, Faggian G, Chiominto B, Mazzucco A, Bortolotti U, Gallucci V. 1990. Heterotopic heart transplantation-a means to increase donor availability. Eur J Cardiothorac Surg 4:202-6.nMangoush O, Bahrami T, De Robertis F, et al. 2004. Regurgitation of the native aortic valve caused by thrombus formation after heterotopic heart transplantation. Ann Thorac Surg 78:1821-3.nMartin J, Siegenthaler MP, Friesewinkel O, et al. 2004. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 25:971-7.nMcMullan DM, Wilansky S, Frazier OH. 2003. Ventricular fibrillation in a heterotopic heart transplant recipient. Ann Thorac Surg 75:598.nNakatani T, Frazier OH, Lammermeier DE, Macris MP, Radovancevic B. 1989. Heterotopic heart transplantation: a reliable option for a select group of high-risk patients. J Heart Transplant 8:40-7.nNewcomb AE, Esmore DS, Rosenfeldt FL, Richardson M, Marasco SF. 2004. Heterotopic heart transplantation: an expanding role in the twenty-first century? Ann Thorac Surg 78:1345-50; discussion 1350-1.nNovitzky D, Cooper DK, Rose AG, Barnard CN. 1984. The value of recipient heart assistance during severe acute rejection following heterotopic cardiac transplantation. J Cardiovasc Surg 25:287-95.nReichenspurner H, Hildebrandt A, Boehm D, et al. 1989. Heterotopic heart transplantation in 1988: recent selective indications and outcome. J Heart Transplant 8:381-6.nRidley PD, Khaghani A, Musumeci F, et al. 1992. Heterotopic heart transplantation and recipient heart operation in ischemic heart disease. Ann Thorac Surg 54:333-7.nRose EA, Gelijns AC, Moskowitz AJ, et al. 2001. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345:1435-43.nSalzberg SP, Lachat ML, von Harbou K, Zund G, Turina MI. 2005. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 27:222-5.nTagusari O, Kormos RL, Kawai A, et al. 1999. Native heart complications after heterotopic heart transplantation: insight into the potential risk of left ventricular assist device. J Heart Lung Transplant 18:1111-9.nVillanueva FS, Murali S, Uretsky BF, et al. 1989. Resolution of severe pulmonary hypertension after heterotopic cardiac transplantation. J Am Coll Cardiol 14:1239-43.nZimpfer D, Zrunek P, Sandner S, et al. 2007. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 31:698-702.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).